Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)
Grössmann, N.
Record ID 32017000162
English
Authors' recommendations:
The treatment with ixazomib in combination with lenalidomide and dexamethasone offers a significant improvement in PFS (median gain 5.9 months, intention-to-treat population). However, the missing data for OS and the lack of benefit of the ixazomib therapy for the actual patient population that is most affected by MM in clinical practice (> 65 years), highlight the requirement for long-term data. Furthermore, the direct comparison of ixazomib to the carfilzomib and elotuzumab triplet combination regimens is necessary to identify the best treatment option for MM patients, who received prior therapies.
Details
Project Status:
Completed
URL for project:
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie/en
Year Published:
2016
URL for published report:
http://eprints.hta.lbg.ac.at/1111/1/DSD_HSO_Nr.63.pdf
URL for additional information:
http://eprints.hta.lbg.ac.at/1111/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Boron Compounds
- Dexamethasone
- Glycine
- Humans
- Multiple Myeloma
- Proteasome Inhibitors
- Thalidomide
- Antineoplastic Combined Chemotherapy Protocols
- Lenalidomide
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.